Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3893018 | 0.91 | CXCL8 (0.40) | CXCL8HTTP4HTMKDM4EAURKA | |
| SCHEMBL3896811 | 0.85 | HTT (0.42) | CXCL8HTTKDM4ERAB9ANPC1 | |
| SCHEMBL14392325 | 0.84 | CXCL8 (0.46) | CXCL8HTTP4HTMKDM4EAURKA | |
| SCHEMBL15630485 | 0.74 | KDM4E (0.54) | CXCL8HTTP4HTMKDM4EAURKA | |
| SCHEMBL5488826 | 0.73 | HCAR2 (0.39) | HTTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL31184770 | 0.73 | HCAR2 (0.39) | HTTKDM4EMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL15645118 | 0.72 | HCAR2 (0.38) | HTTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL9128060 | 0.72 | KDM4E (0.58) | CXCL8HTTP4HTMKDM4EAURKA | |
| SCHEMBL3884629 | 0.71 | CDC7 (0.41) | CXCL8HTTKDM4ERAB9ANPC1 | |
| SCHEMBL4061073 | 0.71 | HCAR2 (0.46) | HTTKDM4EMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103121996-A | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors | SERONO LAB | 2013-05-29 | — | — | CN | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| EP-2013180-A1 | NOVEL HETEROARYL-SUBSTITUTED ARYLAMINOPYRIDINE DERIVATIVES AS MEK INHIBITORS | Laboratoires Serono SA (CH) | 2009-01-14 | — | — | EP | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| WO-2007123936-A1 | NOVEL HETEROARYL-SUBSTITUTED ARYLAMINOPYRIDINE DERIVATIVES AS MEK INHIBITORS | LABORATOIRES SERONO SA (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | NRAS, MAP3K5, MAP3K1 | CXCL8 2011/4885HTT 4456/4885P4HTM 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.